Alba Therapeutics has released preliminary results from its phase IIa clinical trial for AT-1001 in subjects with autoimmune disorder celiac disease.
Subscribe to our email newsletter
Alba’s study, the first phase IIa trial in celiac disease (CD) and the first to assess dosing requirements for AT-1001 in CD, was designed to evaluate the safety, tolerability and efficacy of multiple doses of AT-1001 in CD subjects during a 2-week gluten challenge.
The randomized, double-blind, placebo-controlled clinical trial enrolled 86 patients who were confirmed biopsy positive for CD and in compliance with a gluten-free diet for at least six months prior to enrollment. Patients were randomized into seven drug-treated and placebo groups and challenged three times a day with gluten during a 14-day period.
Four doses of the enteric coated oral formulation of AT-1001, all less than 10 mg, were given prior to each gluten challenge. Study endpoints included intestinal permeability – a marker of disease state in CD – as well as patient symptoms and outcomes.
Patients on the AT-1001 drug performed better than those on the gluten/placebo arm and analyses demonstrated that several symptoms and outcomes improved at statistically significant levels. Safety and tolerability of multiple oral doses of AT-1001 in the patient population was demonstrated, with no severe adverse events reported.
Based on these results, Alba said that it will advance AT-1001 into a phase IIb clinical study in CD subjects during the third quarter of 2007.